RNA Interference Normalizes PAI-1 Levels and Prolongs Lifespan in Murine Models

Systemic chronic inflammation serves as a primary driver for cellular senescence and the progression of age-related metabolic and cardiovascular disorders [1]. Within this inflammatory milieu, the dysregulation of fibrinolysis, the physiological process responsible for degrading blood clots, significantly increases the risk of life-threatening thrombotic events [2]. While traditional management focuses on lipid modification and standard anticoagulation, these approaches often fail to address the underlying molecular shifts that occur as patients age [3, 4]. Emerging evidence suggests that specific proteins within the coagulation cascade may be amenable to highly targeted genetic modulation using small interfering RNA delivered via lipid nanoparticles [5]. A recent study evaluates whether silencing a key inhibitor of fibrinolysis can safely mitigate thrombotic risk and influence the broader trajectory of aging, offering a potential new pathway for managing chronic cardiovascular risk.